<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00018863</url>
  </required_header>
  <id_info>
    <org_study_id>#3761</org_study_id>
    <secondary_id>U01MH060903</secondary_id>
    <secondary_id>U01MH060642</secondary_id>
    <secondary_id>U01MH060943</secondary_id>
    <secondary_id>U01MH060848</secondary_id>
    <secondary_id>U01MH060900</secondary_id>
    <secondary_id>U01MH060833</secondary_id>
    <secondary_id>DSIR CT-M2</secondary_id>
    <nct_id>NCT00018863</nct_id>
  </id_info>
  <brief_title>Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS)</brief_title>
  <official_title>Methylphenidate Efficacy and Safety in ADHD Preschoolers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <brief_summary>
    <textblock>
      This research focuses on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in
      very young children. The medication being used is methylphenidate (Ritalin); it is being
      studied to determine its safety and how well it works to treat ADHD in preschool-age children
      (3-5.5 year olds).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Young children age 3-5.5 years will be studied. The study includes treatment with different
      doses of methylphenidate and placebo; all children will receive active medication during the
      study. Prior to treatment, each child will receive a thorough psychiatric evaluation and each
      guardian will complete a 10-week workshop (2 hours/week). Throughout the study, parents and
      teachers will complete forms that report on the child's behavior and possible side effects.
      Participants will be monitored by regular visits with a study physician. Most participants
      will be involved in the study for up to 16 months to ensure optimal evaluation, dosing, and
      monitoring
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2001</start_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>165</enrollment>
  <condition>Attention Deficit Disorder With Hyperactivity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Boys and girls who are:

          -  Between the ages of 3-5.5 years

          -  Qualified as having ADHD by our diagnostic evaluations and clinical staff

          -  Otherwise generally healthy

          -  Willing, and have parents that are willing, to attend all visits required by the study

          -  Enrolled in some type of day-program: day care, preschool, nursery school,
             kindergarten, for at least 2 half days/week

          -  In classrooms with teachers that are willing to participate by completing rating scale
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence Greenhill, M.D.</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd/index.shtml</url>
    <description>Specific information on ADHD</description>
  </link>
  <reference>
    <citation>Schleifer M, Weiss G, Cohen N, Elman M, Cvejic H, Kruger E. Hyperactivity in preschoolers and the effect of methylphenidate. Am J Orthopsychiatry. 1975 Jan;45(1):38-50. doi: 10.1111/j.1939-0025.1975.tb01164.x.</citation>
    <PMID>1089359</PMID>
  </reference>
  <reference>
    <citation>Handen BL, Feldman HM, Lurier A, Murray PJ. Efficacy of methylphenidate among preschool children with developmental disabilities and ADHD. J Am Acad Child Adolesc Psychiatry. 1999 Jul;38(7):805-12.</citation>
    <PMID>10405497</PMID>
  </reference>
  <reference>
    <citation>Conners CK: Controlled trial of methylphenidate in preschool children with minimal brain dysfunction. Int J Ment Health (4):61-74, 1975.</citation>
  </reference>
  <reference>
    <citation>Barkley RA. The effects of methylphenidate on the interactions of preschool ADHD children with their mothers. J Am Acad Child Adolesc Psychiatry. 1988 May;27(3):336-41.</citation>
    <PMID>3379016</PMID>
  </reference>
  <reference>
    <citation>Mayes SD, Crites DL, Bixler EO, Humphrey FJ 2nd, Mattison RE. Methylphenidate and ADHD: influence of age, IQ and neurodevelopmental status. Dev Med Child Neurol. 1994 Dec;36(12):1099-107.</citation>
    <PMID>7525394</PMID>
  </reference>
  <reference>
    <citation>Musten LM, Firestone P, Pisterman S, Bennett S, Mercer J. Effects of methylphenidate on preschool children with ADHD: cognitive and behavioral functions. J Am Acad Child Adolesc Psychiatry. 1997 Oct;36(10):1407-15.</citation>
    <PMID>9334554</PMID>
  </reference>
  <results_reference>
    <citation>Kollins S, Greenhill L, Swanson J, Wigal S, Abikoff H, McCRACKEN J, Riddle M, McGOUGH J, Vitiello B, Wigal T, Skrobala A, Posner K, Ghuman J, Davies M, Cunningham C, Bauzo A. Rationale, design, and methods of the Preschool ADHD Treatment Study (PATS). J Am Acad Child Adolesc Psychiatry. 2006 Nov;45(11):1275-1283. doi: 10.1097/01.chi.0000235074.86919.dc.</citation>
    <PMID>17023869</PMID>
  </results_reference>
  <results_reference>
    <citation>Swanson J, Greenhill L, Wigal T, Kollins S, Stehli A, Davies M, Chuang S, Vitiello B, Skrobala A, Posner K, Abikoff H, Oatis M, McCRACKEN J, McGOUGH J, Riddle M, Ghuman J, Cunningham C, Wigal S. Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry. 2006 Nov;45(11):1304-1313. doi: 10.1097/01.chi.0000235075.25038.5a.</citation>
    <PMID>17023868</PMID>
  </results_reference>
  <results_reference>
    <citation>Greenhill L, Kollins S, Abikoff H, McCracken J, Riddle M, Swanson J, McGough J, Wigal S, Wigal T, Vitiello B, Skrobala A, Posner K, Ghuman J, Cunningham C, Davies M, Chuang S, Cooper T. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. 2006 Nov;45(11):1284-1293. doi: 10.1097/01.chi.0000235077.32661.61. Erratum in: J Am Acad Child Adolesc Psychiatry. 2007 Jan;46(1):141.</citation>
    <PMID>17023867</PMID>
  </results_reference>
  <results_reference>
    <citation>McGOUGH J, McCRACKEN J, Swanson J, Riddle M, Kollins S, Greenhill L, Abikoff H, Davies M, Chuang S, Wigal T, Wigal S, Posner K, Skrobala A, Kastelic E, Ghuman J, Cunningham C, Shigawa S, Moyzis R, Vitiello B. Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. 2006 Nov;45(11):1314-1322. doi: 10.1097/01.chi.0000235083.40285.08.</citation>
    <PMID>17023870</PMID>
  </results_reference>
  <results_reference>
    <citation>Wigal T, Greenhill L, Chuang S, McGOUGH J, Vitiello B, Skrobala A, Swanson J, Wigal S, Abikoff H, Kollins S, McCRACKEN J, Riddle M, Posner K, Ghuman J, Davies M, Thorp B, Stehli A. Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry. 2006 Nov;45(11):1294-1303. doi: 10.1097/01.chi.0000235082.63156.27.</citation>
    <PMID>17028508</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 5, 2001</study_first_submitted>
  <study_first_submitted_qc>July 6, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2001</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

